News of Note—Freenome bumps up series A to $72M; NxStage wins FDA nod for solo home dialysis

newspaper

> Freenome raised an additional $7 million in series A funding, bringing its total to $72 million. In March, the liquid biopsy player raised $65 million in a round led by Andreessen Horowitz. Release

> The FDA cleared NxStage’s system for solo home dialysis. Patients may now perform hemodialysis at home, without a care partner, during waking hours. Release

> MedGenome bagged $30 million in series C financing—the company will ramp up biomarker discovery programs and further the development of its OncoPept suite of immunotherapy biomarker solutions. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.